Skip to content
ClinCalc Pro
Menu
Calculators Drugs Pathways AI Dx Donate Get the App
Selective RET kinase inhibitor

Selpercatinib (Specialist drug)

Brand names: Retsevmo

Selpercatinib is an oral selective RET kinase inhibitor used as a specialist treatment for RET-fusion-positive non-small-cell lung cancer and RET-altered thyroid cancers.

Dosing — being independently re-sourced

ClinCalc Pro is rebuilding its dose data from primary open sources — the manufacturer SmPC (eMC), the WHO Model Formulary and other official references — under clinician review. This drug's structured dose is not yet published here. Confirm all doses against the product SmPC and your local formulary before prescribing.

Clinical monograph

How it works

It selectively inhibits RET receptor tyrosine kinase signalling driven by RET gene fusions and activating point mutations, suppressing tumour growth.

Prescribing in practice

  • It can prolong the QT interval and cause hepatotoxicity and hypertension, so baseline and periodic ECG, liver function and blood pressure monitoring are required.
  • Patients must have a confirmed RET alteration by a validated test before treatment, which is restricted to specialist oncology services.
  • It is a CYP3A4 substrate with relevant interactions, so co-prescribed strong inhibitors and inducers should be reviewed per current prescribing references.

Monitoring

Monitor ECG (QTc), liver function tests and blood pressure before and during treatment.

Counselling the patient

  • Report fainting, palpitations, yellowing of the skin or severe headache.
  • Tell the team about all other medicines and avoid grapefruit.
  • Attend for regular blood pressure, blood test and ECG checks.

Evidence & guidelines

Use is supported by NICE guidance and the LIBRETTO-001 trial in RET-altered cancers.

Reference: NICE TA760/TA819; SmPC; Drug verified in RxNorm (NLM); confirm dosing against the manufacturer SPC (eMC). Verify against your local formulary and current prescribing references before prescribing. Monograph status: clinician-reviewed (2026-07-04).

Related

Curated clinical cross-links plus same-class fallbacks.

Calculators
Drugs
Pathways